Key Insights

Highlights

Treatment Research

1 treatments under study, led by Rituximabchopalemtuzumab

Research Leaders

6 sponsors active, led by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT00504491Phase 2Withdrawn

R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia

Showing all 1 trials

Research Network

Common Treatments

  • Rituximabchopalemtuzumab1

Active Sponsors

  • Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea1
  • Genzyme, a Sanofi Company1
  • Bayer1
  • Francesc Bosch, MD1
  • CABYC1

Top Investigators

Related Conditions

  • Chronic Lymphocytic Leukaemia1
  • Patients Relapsed With Purines Therapy1

Activity Timeline